First AD

Second AD

Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification 

Dr Garcia-Manero to Panel: How have the updates to WHO (

) and ICC guidelines impacted how you identify, diagnose, and classify myelodysplastic syndromes?

@01:40 –3:00 Dr. Thomas Cluzeau: Please comment on the newest risk stratification tool, IPSS-M. Is this something you are using in practice? What is the impact of this tool in practice?

Dr Komrokji:@3:10 higher risk what to consider does not affect the lower risk.

@4:25 - Dr Oliva: How do you distinguish between patients with pre-MDS (CHIP, CCUS, etc.) and lower-risk MDS?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 

Peer Exchange

The expert panel in hematologyists examines recent WHO and ICC guideline updates, evaluating their impact on the evolving treatment landscape for myelodysplastic syndromes. 